Table 1. Plasma concentrations of biologic markers in patients with sickle cell disease and control participants; results in median (interquartile range).
| Sickle cell disease patients (N = 237) | Controls (N = 43) | P1 | |
| Inflammatory markers | |||
| Interleukin-6 (pg/ml) | 0.8 (0.3–1.6) | 0.4 (0.2–1.3) | 0.031 |
| Interleukin-8 (pg/ml) | 0.4 (0.2–1.1) | 0.3 (0.05–0.7) | 0.001* |
| Interferon-γ (pg/ml) | 40 (16–73) | 34 (11–51) | 0.2 |
| Monocyte chemoattractant protein-1 (pg/ml) | 7.0 (3.7–12.9) | 8.1 (2.3–12.2) | 0.4 |
| Tumor necrosis factor-α (pg/ml) | 25 (6–50) | 10 (2–42) | 0.1 |
| Interleukin-10 (pg/ml) | 1.6 (0.4–5.7) | 1.1 (0.1–2.5) | 0.003* |
| RANTES (ng/ml) | 4.0 (2.4–5.8) | 6.9 (3.5–1.5) | 0.0002* |
| Angiogenic markers | |||
| Fibroblast growth factor (basic) (pg/ml) | 13.5 (3.3–32.5) | 7.2 (5.1–17.0) | 0.009 |
| PDGF- BB (ng/ml) | 0.4 (0.2–0.6) | 0.3 (0.2–0.4) | 0.043 |
| VEGF (pg/ml) | 1.6 (0.3–6.0) | 0.5 (0.1–2.3) | 0.002* |
1
From ANOVA adjusted for hydroxyurea treatment and with best transformation of the variable.
*
Statistically significant after Bonferroni adjustment for multiple comparisons.